Claudia Monsalve Arango

Mamá de un niño, tres gatos y una perrita ▪ Endocrino, diabetes y lipidos ▪ Opiniones personales ▪

[Thomas Dayspring @Drlipid]

So sorry to ruin the day of the Social Media cholesterol deniers. They have no clue that plasma cholesterol metrics have no relationship to cellular (including brain) cholesterol

[Claudia Monsalve Arango @CMons79]

@GataFranca Bo

[Saúl Sánchez @SaulNutri]

🧵 HILO | Lo que comen los niños HOY determina su riesgo cardiovascular MAÑANA 🫀👶

Durante años se pensó que la enfermedad cardiovascular era “cosa de adultos”.

La ciencia ya no opina lo mismo 👇

[Claudia Monsalve Arango @CMons79]

@JagomezR_MD @jsenior64 A mi si me gusta porque promueve el trabajo conjunto pero no creo que debamos poner más nombres.... El asunto comenzó con no darle el nombre que era al síndrome metabólico hace 30 años es decir la obesidad, que finalmente son los estadios iniciales del síndrome CRM

[EHJ Editor-in-Chief @ehj_ed]

Advancements in Lipid-Lowering Therapies: Targeting Key Mechanisms in Lipid and Lipoprotein Metabolism! Read the news in #EHJ!

https://t.co/ZkRrsTZvws

#lipoproteins #EHJ #cardiotwitter @ESC_journals @escardio

[European Atherosclerosis Society @society_eas]

Listen to Prof. @BNordestgaard explain the new recommendations on statin therapy. The update provides clear guidance on primary prevention with statins, outlining:
- the role of statins in preventing future cardiovascular events
- who should or may be considered for statin therapy in primary prevention
- how treatment can be offered to individuals currently free of cardiovascular disease

Click here: https://t.co/JHJ3PwPbJL @ProfKausikRay @KatiOorni

[Dr. Purvi Parwani @purviparwani]

Some great slides from #Guidelines discussion on triglycerides reduction.

Check them out.

📉 Not all TG-lowering therapies equal CV benefit.
•Statins: ↓TG 15–26% ✅ CV benefit
•Fibrates: ↓TG ~26% ❌ no clear CV benefit
•High-dose icosapent ethyl (EPA): ↓TG 20% ✅ CV benefit (REDUCE-IT)
•Volanesorsen: ↓TG 77% ✅ pancreatitis risk reduction

#ESCCongress #Lipidology #CardioTwitter

[Alberto Jiménez @jotalbertojota]

🚨🫀 #ESC2025 en Madrid está dejando MUCHA tela que cortar.

Aquí va un hilo 🧵 con lo más 🔝 para la práctica clínica

(En cristiano, pero científico..)

Spoiler: algunos estudios cambian lo que hacemos mañana en consulta
👇

(A los opositores MIR: esto NO entra❤️🫶😂)

[European Atherosclerosis Society @society_eas]

We are pleased to announce that the European Society of Cardiology (ESC), together with the European Atherosclerosis Society (EAS), has published the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: https://t.co/7KcqJjRchA

Since the publication of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular (CV) risk, there have been several randomized controlled trials that might change patient management ahead of the next scheduled full dyslipidaemia Guidelines.

This 2025 Focused Update addresses changes in recommendations for the treatment of dyslipidaemias based on new evidence published up until March 31, 2025. @ProfKausikRay @KatiOorni

[International Atherosclerosis Society (IAS) @atherosociety]

#FBF to the @society_eas Congress in Glasgow, UK last week! The opportunity to connect with our global network of friends and colleagues is crucial to our work in prevention and management of #atherosclerosis and related cardiometabolic conditions.

Stay tuned for upcoming events IAS will be attending - we'd love to connect!

[Sam Tsimikas, MD @Lpa_Doc]

A BIG moment just dropped: The design of the Lp(a)HORIZON trial is now published.

https://t.co/HuuLk61ezn

Brief summary:
1- 8,323 patients
2- median Lp(a) level of 108 mg/dL and 236 nmol/L - higher than likely anticipated
3- 79% of patients were ≥90 mg/dL - higher than likely anticipated
4- Median baseline LDL-C- 65 mg/dL - lowest of any CVOT in history.
5- >80% had a prior MI, 10% had ischemic stroke and 14% had symptomatic peripheral artery disease.
6- 37% ahistory of premature MI or stroke events
7- Awaiting 993 endpoint events, all patients will have minimum 2.5 years of follow up
8- 90% power to detect a hazard ratio of approximately 0.80 for the primary endpoint in Lp(a) >70 mg/dL, and 0.75 in the subpopulation of Lp(a) >90 mg/dL.
9- Two interim analyses planned by data monitoring committee.

The Lp(a) Hypothesis will be revealed at end of the study completion. We are almost there on the very long wait...

[Claudia Monsalve Arango @CMons79]

@SIAC_cardio @AnaGMuneraE @siacprevent @cardiologiaec @vladullauri1 @adribaran @aracelilm @Risantilopezcar @MujerSIAC @SIAComunidad @ElectroSIAC1 @cifacah @SIAC_MCP @EmergenciasSiac Felicitaciones doctora Anita

[Claudia Monsalve Arango @CMons79]

@drpablocorral CAC 0 no es igual no tener estatinas ni a suspenderla, es hacer una valoración de riesgo precisa y seleccionar el paciente qué más se beneficia de la intervención

[Claudia Monsalve Arango @CMons79]

@gustavendocrino Tavo soy partidaria de tratar teniendo en cuenta en riesgo acumulativo por la exposicion al LDL, sin embargo, el la decisicion debe ser compartida con el paciente, utilizo dosis bajas de estatinas y evaluo la posibilidad de efectos adversos

[endocrinogustavoparra 🇨🇴 @gustavendocrino]

100 recomendaciones FÁCILES
para tener salud,
basado en la evidencia,
dentro de la cotidianidad.

[Asoc. Col. Endocrino @ENDOCRINO_COL]

Participa en el SIMPOSIO PRESENCIAL en Medellín - Dislipidemias: Manejo y tratamiento, sábado 6 de julio en el 📷Hotel InterContinental en la Calle 16, Variante # 28 - 51.
Inscríbete aquí: https://t.co/gGtQ64RBCu

@alejoromanmd @esdrasmvm @CMons79

[Claudia Monsalve Arango @CMons79]

@kingsleague_am @maluma 1

[Cardiac Trials @CardiacTrials]

🔑 concept: LDL-Years

Increasing evidence suggests that we can think of lifetime LDL exposure much the same as we can smoking, with pack-year history

Higher LDL x higher span of years —> increased risk

#meded #prevention

[Dr. Abraham Katime Zuñiga @katimeinfecto]

Estatinas en pacientes con Infección por VIH, más allá del LDL colesterol (estudio REPRIEVE)
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.
https://t.co/JutCrBlEP8

[Atherosclerosis @ATHjournal]

Lipid levels are affected by specific transition periods in girls/women such as the menstrual cycle, pregnancy, breastfeeding and menopause
🔗https://t.co/ayTXLAjgOw
@HolvenKirsten @j_rvl @society_eas